Hot Paths

Genentech in up to $2.3B deal with Hanmi for novel weight loss drug

Genentech headquarters

JasonDoiy

  • Roche (RHHBY) unit Genentech has entered into a licensing agreement with Hanmi Pharmaceutical for the South Korean drugmaker’s novel obesity candidate, HM17321.
  • Terms call for Hanmi to receive a $190M upfront payment. The deal value could reach $2.3B with milestone payments plus tiered
Exit mobile version